Posts by Lida P. Hariri, MD, PhD
-
Vaping-associated Chronic Lung Disease: Q&A With Lida Hariri, MD, PhD
The use of electronic cigarettes and vaping has become increasingly popular, with little knowledge of potential long-term health risks. Lida Hariri, MD, PhD, discusses how her recent study of vaping-associated chronic lung disease paves the way to understanding the health risks of vaping.
-
Endobronchial Optical Coherence Tomography Aids Diagnosis of Interstitial Lung Disease
Researchers from the Division of Pulmonary and Critical Care Medicine and Department of Pathology found in a prospective study that endobronchial optical coherence tomography, a minimally invasive, real-time imaging modality, is highly accurate for microscopic diagnosis of interstitial lung disease, notably histopathologic diagnosis of usual interstitial pneumonia in patients with a clinical diagnosis of idiopathic pulmonary fibrosis.
-
2018 Guidelines Perform Well for Diagnosis of Idiopathic Pulmonary Fibrosis
Radiologist interpretations of CT scans aligned well with pathologist interpretations of biopsy data when the categorization schemes of the 2018 ATS/ERS/JRS/ALAT and Fleischner Society guidelines for diagnosing idiopathic pulmonary fibrosis were applied in routine practice at Massachusetts General Hospital.
-
Review: What Clinicians Need to Know About Vaping-related Lung Injury
Lida P. Hariri, MD, PhD, of the Department of Pathology at Massachusetts General Hospital, and colleagues review what clinicians should know about E-cigarette or vaping product use-associated lung injury.
-
Histopathology of COVID-19 Is Typical of Acute Respiratory Distress Syndrome
By reviewing autopsy and biopsy studies, Massachusetts General Hospital researchers have shown that COVID-19 manifests principally as diffuse alveolar damage, the histopathologic pattern typically associated with acute respiratory distress syndrome.
-
ARDS Related to COVID-19 Expected to Cause Increase of Pulmonary Fibrosis
Within the next year, physicians can expect to see increased numbers of patients with fibrotic lung disease that has developed as a complication of acute respiratory distress syndrome related to COVID-19.
-
Will COVID-19 cause more IPF?
Many people are saying ... with high rates of COVID-19 ARDS, we will be seeing more pulmonary fibrosis in the coming years.
-
What Kind of Lung Disease Does SARS-CoV-2 Cause?
According to Massachusetts General Hospital researchers, the histologic evidence to date predominantly confirms clinical observations that the respiratory failure in severe COVID-19 is attributable to acute respiratory distress syndrome.
-
Lung Pathology in COVID-19
Both in the scientific literature and on social media, it has been alleged that respiratory failure in COVID-19 represents a novel and unique entity.
Biography
Lida Hariri, MD, PhD, is an assistant pathologist in the Department of Pathology and Division of Pulmonary and Critical Care Medicine at Massachusetts General Hospital and an Associate Professor of Pathology at Harvard Medical School. She received her PhD in Biomedical Engineering in 2007 and MD in 2009 from the University of Arizona.
